These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20944153)

  • 1. Novel chemoradiosensitizers for cancer therapy.
    Page P; Yang LX
    Anticancer Res; 2010 Sep; 30(9):3675-82. PubMed ID: 20944153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging radiosensitizers and radioprotectors.
    Spalding AC; Lawrence TS
    Cancer Invest; 2006; 24(4):444-56. PubMed ID: 16777698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
    Chen AY; Chou R; Shih SJ; Lau D; Gandara D
    Crit Rev Oncol Hematol; 2004 May; 50(2):111-9. PubMed ID: 15157660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New radiosensitizing regimens, drugs, prodrugs, and candidates.
    Vallerga AK; Zarling DA; Kinsella TJ
    Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin.
    Coughlin CT; Richmond RC
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):31-43. PubMed ID: 2669136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of radiotherapy by radiosensitizers and cancer chemotherapeutic agents. II. Cancer chemotherapeutic agents.
    Looney WB; Hopkins HA
    Semin Oncol; 1989 Jun; 16(3):176-9. PubMed ID: 2658081
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; FĂ©lix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Past, current and future protocols for combined modality therapy in childhood medulloblastoma.
    Kaaijk P; Schouten-van Meeteren AY; Slotman BJ; Kaspers GJ
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):79-90. PubMed ID: 12597352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions.
    Bentzen SM; Harari PM; Bernier J
    Nat Clin Pract Oncol; 2007 Mar; 4(3):172-80. PubMed ID: 17327857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
    Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
    Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers.
    Coleman CN
    Semin Oncol; 1989 Jun; 16(3):169-75. PubMed ID: 2658080
    [No Abstract]   [Full Text] [Related]  

  • 12. [Perspectives in biological modulation of radiotherapy].
    Deutsch E; Huguet F
    Bull Cancer; 2005 Jan; 92(1):90-6. PubMed ID: 16123013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
    Miller AR; Pisters PW; Lee JE; Janjan NA; Abbruzzese JL; Evans DB
    Hepatogastroenterology; 1998; 45(21):624-33. PubMed ID: 9684107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
    Khuntia D; Mehta M
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
    Piekarz RL; Sackett DL; Bates SE
    Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
    Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
    Dunst J; Haensgen G
    Strahlenther Onkol; 2001 Dec; 177(12):635-40. PubMed ID: 11789401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for enhancing viral-based gene therapy using ionizing radiation.
    Chmura SJ; Advani SJ; Kufe DW; Weichselbaum RR
    Radiat Oncol Investig; 1999; 7(5):261-9. PubMed ID: 10580895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.